AAREYDRUGS.NSAAREYDRUGS.NSNSE
Loading
EBITDA Margin Over TimeContracting
Percentile Rank33
3Y CAGR-6.9%
5Y CAGR-9.7%
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

3Y CAGR
-6.9%/yr
vs -3.3%/yr prior
5Y CAGR
-9.7%/yr
Consistent
Acceleration
-3.6pp
Decelerating
Percentile
P33
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
2 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM2.01%-21.0%
20252.55%-11.9%
20242.89%+15.8%
20232.49%-12.8%
20222.86%-14.7%
20213.35%+38.8%
20202.42%-15.5%
20192.86%+20.9%
20182.36%-4.7%
20172.48%-